N/A N=51 Cardiovascular Complications of Sickle Cell Disease
Sickle Cell Disease
Primary: MRI Parameter - LVEDVi, mL/cm2 (Measured Using Method of Disks, Controls Serve as Normal Ranges) — 124.0; 78.7 mL/cm2 — p=0.0039
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=119 Early Identification of Myocardial Impairment in PBC
Primary Biliary Cholangitis · Cardiovascular Abnormalities
Primary: The Incidence of Cardiac Events — 0; 0; 0; 0 Participants — p=0.001
N/A N=22 Endothelial Function and Cardiac Output in RV Pacing
Bradycardia
Primary: Endothelial Function Assessed by Flow Mediated Vasodilatation — 1.96; 1.73 EndoPAT index (EnFI)
N/A N=120 Training-induced Increased Left Ventricular Trabeculation
Athletes Heart · Left Ventricular Hypertrabeculation
Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44
N/A N=151 Systemic Lupus Erythematous and Heart Conduction Disorders
Lupus Erythematosus, Systemic · Atrioventricular Block · Sudden Death
Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
N/A N=60 Heart Function in HIV-Negative Children Exposed to HIV and HAART
HIV Infections
Primary: Left Ventricular Mass Index — 67; 60 g/m2 — p=0.27
Phase 4 N=76 Cardiovascular Function in COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI) in the 6th Week of Treatment — 2.855; 2.317 Millilitre/ meter^2 (mL/m^2) — p=0.6331
N/A N=17 Evaluating the Influence of Apnea on Cardiac Function Using Cardiac Magnetic Resonance Imaging.
Physiological Changes in Deliberate Apnea
Primary: Cardiac Function: Duration of Apnea — 483 sec
Phase 4 N=130 Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes · Coronary Heart Disease
Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01
N/A N=33 Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease
Sickle Cell Disease
Primary: Frequency of the Diffuse Myocardial Fibrosis Phenotype — 5; 10; 10; 1 Participants
N/A N=2,039 Pathways to Cardiovascular Disease Prevention (DCRI Central and Statistical Coordinating Center)
HIV/AIDS · Cardiovascular Diseases
Primary: Number of Participants With Visit to a Cardiology Specialist From Cohort — 283 Participants
N/A N=165 Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy
Congenital Heart Disease
Primary: To Evaluate the Incidence of the Pre-proendothelin SNP at Nucleotide 5665 — 10 participants
N/A N=123 Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients
Hypertension · High Blood Pressure · Ventricular Hypertrophy
Primary: Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life — -3.3; -4.9 mm Hg
N/A N=10 Pacemaker Therapy in Adults With Congenital Heart Defects
Congenital Disorder
Primary: Feasibility of Pacemaker Implant With Total Thoracoscopic Approach to Epicardial Pacing Lead — 100 percentage of particiapants
N/A N=33 Noninvasive Measurement of CO Using Impedance Cardiography in Patients With CHD
Congenital Heart Disease
Primary: Mean Difference in Stroke Volume Between CMR and SMIC — 1.7 ml — p=0.47
Phase 4 N=30 Cardiovascular Effects of Adderall in Healthy Adults.
Hemodynamics · Cardiovascular System
Primary: Systolic Blood Pressure — 116; 116; 126; 115 mmHg
Phase 3 N=22 Coronary Artery Vasculopathy in Pediatric Heart Transplant Patients
Orthotopic Heart Transplant
Primary: Coronary Flow Reserve (CFR) — 1.77 ratio: peak to baseline CFV
N/A N=86,939 The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events
Parkinson's Disease · Hyperprolactinemia
Primary: Number of Participants With Fibrotic Valvular Heart Disease Per 10,000 Participant-Years of Follow-Up — 21; 21; NA; 52 Participants/10,000 Participant-Years
N/A N=65 Singing and Cardiovascular Health in Older Adults
Cardiovascular Diseases · Cardiovascular Risk Factor · Cardiovascular Health
Primary: Change in FMD% — -0.06; -0.11; -0.06 FMD percent — p=0.864
N/A N=657 Measuring Cardiovascular Performance and Blood Flow Using Common But Never Compared Methods.
D012039 · D001775
Primary: Feasibility of Performing Echo, BNP, and VP on Human Subjects. — 657; 236 Participants
Early Phase 1 N=23 Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia
Preeclampsia
Primary: Microvascular Endothelial Function (Cutaneous Conductance, %Maximum) — 95; 77 % of maximal cutaneous conductance
N/A N=77 Complement and Cardiovascular Risk in Adolescents
Cardiovascular Disease · Type 2 Diabetes
Primary: Complement C3 Genotype — 22; 45; 2; 6 Participants
Phase 4 N=53 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
Myocardial Fibrosis · Hypertrophic Cardiomyopathy
Primary: Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo. — 2.1; 2.1; 0.7…
N/A N=8 Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients
Arrhythmias, Cardiac
Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants
N/A N=50 Cardiac Function and Metabolism in Young Adults Born Premature (PET-MRI)
Infant,Premature
Primary: Cardiac Glucose Uptake During Normoxic Rest (µg/Min) — 0.689; 0.540 µg/min — p=0.38
N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
Phase 2 N=19 Blood Flow and Vascular Function in Cystic Fibrosis
Cystic Fibrosis
Primary: Acute Study: Percentage Flow-Mediated Dilation (FMD) — 7.8; 7.7; 7.3; 6.6 percent flow mediated dilation
N/A N=347 Communicating Health Information and Improving Coordination With Primary Care
Hypertension · Dyslipidemias · Diabetes
Primary: Undertreatment of Hypertension (>=140/90 mmHg), Dyslipidemia (LDL >=160 mg/dL or Triglyceride >=150 mg/dL), and/or Glucose Intolerance (if Prediabetes, Hemoglobin A1c…
N/A N=10 Transcutaneous Stimulation in Spinal Cord Injury
Spinal Cord Injury
Primary: Seated Systolic Blood Pressure — 86; 100.4; 102.7; 101.3 mmHg
N/A N=36 Exercise,Metabolic Syndrome and Weight Regain (Echocardiography Substudy)
Metabolic Syndrome · Obesity
Primary: Mean Resting E/E' — 7.01 ml/min/kg — p==0.14